AIDS

The Inner Circle acknowledges Sharon E. Oster, MD, as a Pinnacle Life Member

Retrieved on: 
Monday, March 11, 2024
Internal medicine, Phi Beta Kappa, AIDS, ASM, Patient, University, MD, Medical Center, Infection, Society, Love, ID, Inner circle, Pharmaceutical industry

BOISE, Idaho, March 11, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Sharon E. Oster, MD, is acknowledged as a Pinnacle Life Member for her contributions to the fields of Internal Medicine and Infectious Diseases.

Key Points: 
  • BOISE, Idaho, March 11, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Sharon E. Oster, MD, is acknowledged as a Pinnacle Life Member for her contributions to the fields of Internal Medicine and Infectious Diseases.
  • She followed this accomplishment at East Virginia Medical School where she completed a medical degree in 1980.
  • Recognized as the Resident of the Year award, the doctor completed her residency at the Veterans Administration (VA) Medical Center.
  • Considered a leader in her field, Dr. Oster is considered an expert in internal medicine and infectious diseases.

DIFFA'S STAR-STUDDED 40TH ANNIVERSARY GALA TICKETS ON SALE NOW

Retrieved on: 
Wednesday, March 6, 2024
Herman Miller, LGBTQ, Lighthouse, PRIDE, HOK, AIDS, Friends, Chelsea Piers, David Rockwell, FIT, Heel, Hope, SVA, Homelessness, Human, Hetrick-Martin Institute, Fashion, Gala, Table, Callen-Lorde Community Health Center, Council, Organization, Creativity, NYSID, SAGE, Steelcase, Housing Works, CFDA, Face, Student, Nightclub

New York, NY, March 06, 2024 (GLOBE NEWSWIRE) -- DIFFA is excited to announce its highly anticipated 40th Anniversary Gala on Thursday, March 28th at the Lighthouse at Chelsea Piers.

Key Points: 
  • New York, NY, March 06, 2024 (GLOBE NEWSWIRE) -- DIFFA is excited to announce its highly anticipated 40th Anniversary Gala on Thursday, March 28th at the Lighthouse at Chelsea Piers.
  • The Gala will commemorate a remarkable legacy—forty years of impactful DIFFA initiatives—and raise critical funds to further support these vital causes.
  • DIFFA is deeply grateful to Benjamin Moore, presenting sponsor of the 40th Anniversary Gala, as well as gold sponsors Empire Office with Steelcase, EvensonBest, HOK, MillerKnoll, Rockwell Group, and Shaw Contract.
  • The DIFFA gala is just one in several 40th anniversary fundraising events.

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Retrieved on: 
Tuesday, March 5, 2024
Infection, Fungal infection, CROI, NIH, AIDS, Vaccine Research Center, ACTG, Conference, Antibody, Safety, OPKO Health, Therapy, Pharmacokinetics, AIDS Clinical Trials Group, Modex, Trial of the century, HIV, HIV/AIDS, Immune system, Vaccine

WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency virus (HIV), at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection.

Key Points: 
  • These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection.
  • The study enrolled 52 participants and was conducted by the AIDS Clinical Trials Group (ACTG), a clinical trials network funded by the National Institute of Allergy and Infectious Diseases, NIH.
  • The antibody was safe and well-tolerated at all dose levels and via both intravenous and subcutaneous administration.
  • These clinical data on an HIV multispecific antibody inform the future advancement of such antibodies for the prevention and treatment of HIV and provide strong rationale for the development of current and future antibody products.

Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging

Retrieved on: 
Friday, February 23, 2024
Methylation, Dysbiosis, Culture, Penn Center, Health, Bacteria, University, Subtypes of HIV, Life Length, Wistar Institute, Bangladesh Technical Education Board, Ileum, Infection, NIH, AIDS, Glass, Metabolomics, Nucleotide, DSM-IV codes, Biomedical Research, HIV/AIDS research, Wistar, University of Pittsburgh, DNA, Immune system, National Institutes of Health, Leiden University Medical Center, Weill Cornell Medicine, Hannum, Research, Inflammation, Blood, Ageing, Cancer, Cell biology, Microbiome, Rush University, HIV, DNA methylation, Vaccine

Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.

Key Points: 
  • Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.
  • A prime suspect in this aging puzzle is the gut microbiome and its potential leakage into the bloodstream.
  • The Abdel-Mohsen lab investigates how gut leakage can impact the immune system and lead to chronic inflammation, which may accelerate aging.
  • Their analysis revealed a significant connection between disrupted gut microbiomes, increased intestinal permeability (leaky gut), and faster biological aging.

Soleo Health Celebrates 10 Years of Simplifying Complex Care for Patients

Retrieved on: 
Thursday, March 7, 2024
Oncology, Research, Software, Medical Devices, Infectious Diseases, Hospitals, Genetics, Fitness & Nutrition, Science, Technology, Clinical Trials, Nursing, Cardiology, Medical Supplies, Biotechnology, FDA, Surgery, Diabetes, AIDS, Insurance, Health, Professional Services, Practice Management, Managed Care, Other Health, General Health, Radiology, Pharmaceutical, Pharmacy, Standard of care, Patient, Hospital

Soleo Health , a national leader in complex specialty pharmacy services, recently marked its 10th anniversary on February 24, 2024.

Key Points: 
  • Soleo Health , a national leader in complex specialty pharmacy services, recently marked its 10th anniversary on February 24, 2024.
  • Led by Chief Executive Officer Drew Walk and Chief Commercial Officer Craig Vollmer, Soleo Health was founded on the commitment to simplify complex care for patients.
  • Over the past decade, Soleo Health has become one of the fastest-growing independent specialty pharmacies, solidifying its position as a leading provider of complex specialty pharmacy services.
  • “Looking ahead, we remain dedicated to defining the unique requirements of complex specialty pharmacy, focusing on patients with complex, rare and ultra-rare diseases,” explained Walk.

Women’s Empowerment = Healthy Women: Join AHF on International Women’s Day

Retrieved on: 
Friday, March 8, 2024
AIDS, Health, Family, Consumer, Public Policy, Government, Advocacy Group Opinion, Philanthropy, Children, General Health, Foundation, White House, Federal Government, Women, State, Local, International, Woman, Education, AIDS Healthcare Foundation, AHF, IWD, Policy, HIV, Public, Birth control

“Without healthy women, we cannot have a healthy world – making International Women’s Day the perfect commemoration to raise awareness of the many issues, including harmful inequities, stigma, and discrimination, women of all ages globally face that keep them from succeeding in their lives,” said AHF Deputy Chief of Global Advocacy & Policy Loretta Wong.

Key Points: 
  • “Without healthy women, we cannot have a healthy world – making International Women’s Day the perfect commemoration to raise awareness of the many issues, including harmful inequities, stigma, and discrimination, women of all ages globally face that keep them from succeeding in their lives,” said AHF Deputy Chief of Global Advocacy & Policy Loretta Wong.
  • International Women’s Day was founded in 1911 and is observed annually on March 8.
  • The day recognizes the political, cultural, and economic achievements of women to accelerate their rights.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

Retrieved on: 
Wednesday, March 6, 2024
Pharmaceutical, AIDS, Health, Clinical Trials, Infection, Bangladesh Technical Education Board, SHIV, AD8, Research, Virology, BCG, NIAID, FDA, Safety, Animal, Hook effect, NMIBC, Rockefeller University, ART, Viremia, Patient, NK, Harvard Medical School, HIV, HIV/AIDS, Immune system, Vaccine

Treatment with N-803 and bNAbs led to immune activation and transient viremia, but only limited reductions in the SHIV reservoir.

Key Points: 
  • Treatment with N-803 and bNAbs led to immune activation and transient viremia, but only limited reductions in the SHIV reservoir.
  • Upon ART discontinuation, all animals experienced viral rebound, followed by long-term virus control for up to 10 months in approximately 70% of those treated with N-803 and bNAbs.
  • “When combined with broadly neutralizing antibodies, N-803 has the potential to provide viral control without significant reduction in the viral reservoir, which further suggests that the complete eradication of this reservoir may not be required to induce sustained remission after discontinuing antiretroviral therapy."
  • Safety and efficacy have not been established by any Health Authority or Agency, including the FDA.

Protest: Post Office Won’t Deliver Skid Row Mail

Retrieved on: 
Wednesday, March 6, 2024
Legal, Advocacy Group Opinion, Public Policy, Government, Professional Services, AIDS, White House, Federal Government, Health, State, Local, HHR, AIDS Healthcare Foundation, USPS, HHF, Skid row, AHF, Housing, The Postal Service, Tenant, Homelessness, Human, Louis DeJoy, SRO

AHF complied with the law and installed USPS-approved mailboxes for all the tenants at the SRO buildings that AHF owns and operates.

Key Points: 
  • AHF complied with the law and installed USPS-approved mailboxes for all the tenants at the SRO buildings that AHF owns and operates.
  • For several years and on many occasions, AHF informally asked the USPS to deliver mail properly to its Skid Row properties and even filed a formal administrative claim with the USPS to get a change in delivery to no avail.
  • The case is Shawn Jenkins and AIDS Healthcare Foundation vs. USPS, Louis DeJoy & Six … ( Case No.
  • In 2017, under its Healthy Housing Foundation division, AHF began purchasing and repurposing SRO hotels to address the escalating homelessness and affordable housing crises.

Corporate Greed Sidelines Health Equity at the WTO, says AHF

Retrieved on: 
Wednesday, March 6, 2024
AIDS, Public Policy, Government, Health, Advocacy Group Opinion, COVID-19, Pharmaceutical, World Trade Organization, Therapy, AHF, Face, Safety, AIDS Healthcare Foundation, Pandemic

“This decision is a setback for global health equity, which will sadly have repercussions for future pandemics far beyond COVID-19,” said AHF President Michael Weinstein.

Key Points: 
  • “This decision is a setback for global health equity, which will sadly have repercussions for future pandemics far beyond COVID-19,” said AHF President Michael Weinstein.
  • ”The choice to protect corporate interests and patents on crucial medical innovations during global health emergencies flies in the face of our shared responsibility and the need for solidarity on global public health.
  • It deepens existing health disparities, hindering access to life-saving interventions, especially in low-income countries.”
    Despite the disappointing WTO decision, AHF calls upon the international community, policymakers, and stakeholders to continue advocating for a more just and equitable global health system.
  • The world needs collaborative efforts to address health challenges and ensure the health and safety of all individuals, regardless of geographic location or economic status.

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, AIDS, Hospitals, Health, Pharmaceutical, ARV, Week, Research, Doctor of Philosophy, CROI, Science, CAPRISA, TLD, Fever, Coinfection, TB, STR, Common, Health care, Organization, DTG, Drug resistance, Genotype, HBV, Fungal infection, Principal, Rifampicin, Seroconversion, Tablet, ALT, TDF, Conference, Safety, Biomarker, Pharmacokinetics, Integrase, Metabolism, Emtricitabine, Aes, Gilead Sciences, MD, FDA, Upper respiratory tract infection, Food, Cell, Risk, Prevalence, COVID-19, Death, Patient, HIV/AIDS, Tuberculosis, INSIGHT, HIV, Vaccine

“People with HIV and comorbid conditions or pre-existing treatment resistance can often face complex and evolving treatment needs.

Key Points: 
  • “People with HIV and comorbid conditions or pre-existing treatment resistance can often face complex and evolving treatment needs.
  • The ALLIANCE trial is the first randomized clinical trial of TAF- vs TDF-based regimens in treatment naïve adults with HIV /HBV coinfection.
  • Additionally, ALLIANCE participants treated with Biktarvy exhibited numerically higher levels of HBV viral suppression and seroconversion.
  • The primary outcome measure is viral suppression rates at Week 24, defined as HIV-1 RNA ˂50 copies/mL.